Claudine Gallagher: Depository Trust & Clearing Corporation (DTCC) member of the board. She is Managing Director and Head of Securities Services, Americas, for BNP Paribas. She is responsible for the strategic development of the region, spearheading its client and product development, and marketing initiatives. She joined the firm in 2012 as Head of North America for Securities Services. Prior to joining BNP Paribas, Gallagher was an executive at J.P. Morgan for 10 years in a variety of senior management roles. In her most recent role there, she was global head of Depositary Receipts (DRs), a position she had held since 2006. At BNP Paribas, she serves on various senior committees throughout the Bank, including the Executive Committees of the BNP Paribas Americas Territory and of BNP Paribas Securities Services.
Subject: Shawn K. Feeney
Subject of Interest
Shawn K. Feeney: Depository Trust & Clearing Corporation (DTCC) member of the board. He is a Managing Director at Citigroup and Chief Administrative Officer for Markets and Securities Services, which consists of institutional sales and trading, distribution and research activities spanning a broad range of asset classes and products. Previously, Feeney spent eight years as the Lead Finance Officer for Global Markets. He has also served as Global Fixed Income’s Chief Financial Officer and its Chief Administrative Officer.
Subject: Robert Druskin
Subject of Interest
Robert Druskin: Depository Trust & Clearing Corporation (DTCC) member of the board. He is Non-Executive Chairman of DTCC’s Board and Chairman of the Board Executive Committee. Druskin served as Executive Chairman from April 2011 to December 31, 2015. Previously, Druskin was Lead Director of E*Trade from May through December 2009, interim Chief Executive Officer from December 2009 to March 2010, and Chairman of the Board from December 2009 to March 2011.
Subject: Deborah Cunningham
Subject of Interest
Debbie Cunningham: Depository Trust & Clearing Corporation (DTCC) member of the board. She is Chief Investment Officer of Global Liquidity Markets at Federated Hermes, Inc. She joined Federated in 1981 as a performance analyst and has more than 30 years of investment experience. Since 1990 she has been a portfolio manager for all government and prime liquidity products. In 1994 she took over the management of the taxable liquidity group.
Subject: Robert L. D. Colby
Subject of Interest
Robert L.D. Colby: Depository Trust & Clearing Corporation (DTCC) member of the board. He is Chief Legal Officer of FINRA where he oversees FINRA’s rulemaking, interpretive, and corporate legal functions, as well as FINRA’s Advertising, Corporate Financing and Dispute Resolution Departments, and FINRA’s Appellate Office. Before joining FINRA, Colby was a partner in the law firm of Davis Polk & Wardwell LLP, where he advised on regulatory and compliance matters involving securities and derivatives for financial institutions and markets.
Subject: Michael Bodson
Subject of Interest
Michael C. Bodson: Depository Trust & Clearing Corporation (DTCC) member of the board. He is President and Chief Executive Officer of DTCC. He is also President and Chief Executive Officer of DTCC’s principal operating subsidiaries, DTC, FICC and NSCC and a member of DTCC’s Board of Directors. In his prior position as DTCC’s Chief Operating Officer, Bodson had enterprise-wide responsibility for all Information Technology and Operations and oversaw DTCC Deriv/SERV LLC and EuroCCP. He previously served as Chairman of various DTCC subsidiaries, including Deriv/SERV and Omgeo.
Subject: Depository Trust Clearing Corporation (DTCC)
Subject of Interest
The Depository Trust & Clearing Corporation (DTCC) is an American post-trade financial services company providing clearing and settlement services to the financial markets. It performs the exchange of securities on behalf of buyers and sellers and functions as a central securities depository by providing central custody of securities.
Continue reading “Subject: Depository Trust Clearing Corporation (DTCC)”
Audio (23:01): Eric’s Weekly Wrap-Up Special on Naked Short Selling
Video
From 14:20 mark for a few minutes. multi billionaire Eric Sprott talks about counterfeit shares. He owns Rio2.
Release: INVESTIGATION ALERT The Schall Law Firm Announces it is Investigating Claims Against Carnival Corporation & Plc and Encourages Investors with Losses of $100,000 to Contact the Firm
Release1 May 2020
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Carnival Corporation & Plc (“Carnival” or “the Company”) (NYSE:CCL) for violations of the securities laws.
Analyst: Swayampakula Ramakanth, Ph.D.
AnalystDr. Swayampakula Ramakanth is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Ramakanth’s research covers companies operating in oncology, wound health, medical devices, spine health and animal health. Dr. Ramakanth possesses over ten years of experience as a Life Sciences Equity Analyst as well as seven years of biotechnology industry experience. Prior to joining H.C. Wainwright, Dr. Ramakanth worked as a Junior Analyst at both Jefferies and Merrill Lynch covering large cap pharmaceuticals.
Analyst: Edward White
AnalystEdward White is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on both the biotechnology and the specialty pharmaceutical sectors. Mr. White’s expertise covers companies operating in the oncology, immune-oncology, infectious disease, and gastrointestinal sectors. Prior to working at H.C. Wainwright, Mr. White has worked as a Wall Street Healthcare Analyst, on both the buy-side and the sell-side, since 1996. Mr. White’s previous sell-side experience includes working for Fahnestock & Company (now Oppenheimer), Gerard, Klauer, Mattison & Company (now BMO Capital Markets), Deutsche Bank Securities, and a couple of boutique firms.
Analyst: Doug Tsao
Analyst
Doug Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals. Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies.
Analyst: Raghuram Selvaraju Ph.D.
Analyst
Dr. Raghuram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Selvaraju possesses over a decade’s worth of experience in Healthcare Equity Research. Dr. Selvaraju was ranked by both the StarMine for his earnings accuracy and by The Wall Street journal’s annual Best on the Street Analyst for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he discussed drug development trends, healthcare reform policy, and pharma and biotech M&A.
Analyst: Joseph Pantginis, Ph.D.
Analyst
Dr. Joseph Pantginis is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Pantginis conducted more than seventeen years of healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis worked as a Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Dr. Pantginis also held senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.
Analyst: Oren G. Livnat
Analyst
Oren G. Livnat is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the specialty pharmaceutical industry. Mr. Livnat conducted more than twelve years of research on both the sell-side and the buy-side. Prior to joining H.C. Wainwright, Mr. Livnat worked as a Senior Analyst covering specialty and generic pharma at Iguana Healthcare Partners, a dedicated healthcare long/short hedge fund. Mr. Livnat began his career as an Associate at Natixis Bleichroeder and successively worked as a Senior Analyst at JMP Securities covering both commercial and development-stage companies.
